Sarepta EVP has 830 shares withheld for taxes

Sarepta Therapeutics, Inc. executive vice president and general counsel Cristin Rothfuss reported routine share dispositions related to tax withholding.

Rhea-AI Filing Summary

Sarepta Therapeutics, Inc. executive vice president and general counsel Cristin Rothfuss reported routine share dispositions related to tax withholding. The company withheld a total of 830 shares of common stock at $16.95 per share to cover tax obligations on restricted stock units that vested from grants dated March 7, 2022 and March 6, 2023. Following these tax-withholding entries, Rothfuss directly holds 138,518 shares of Sarepta common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 830 shares

Exercise Price or Tax Liability 2 txns

Insider Rothfuss Cristin

Role EVP, General Counsel

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	484	$16.95	$8K
Exercise Price or Tax Liability	Common Stock	346	$16.95	$6K

Holdings After Transaction: Common Stock — 138,518 shares (Direct)

Footnotes (2)

1. F1. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022.
2. F2. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Sarepta (SRPT) EVP Cristin Rothfuss report?

Cristin Rothfuss reported routine tax-related share dispositions. Sarepta withheld 830 shares of common stock to satisfy tax obligations tied to vesting restricted stock units granted in 2022 and 2023, rather than selling shares in an open-market trade.

How many Sarepta (SRPT) shares were withheld for taxes in this Form 4?

A total of 830 Sarepta common shares were withheld for taxes. The Form 4 shows two transactions: 484 shares and 346 shares, both at $16.95 per share, to cover tax withholding on vesting restricted stock units.

What is Cristin Rothfuss’s Sarepta (SRPT) share ownership after the tax withholding?

After the reported tax-withholding dispositions, Cristin Rothfuss directly owns 138,518 Sarepta common shares. This figure reflects her holdings following the 830 shares withheld by the company to satisfy tax obligations on vesting restricted stock units.

Were the Sarepta (SRPT) insider transactions open-market sales?

The transactions were not open-market sales. According to the filing, Sarepta withheld shares to satisfy tax withholding obligations on vesting restricted stock units, a non-market mechanism classified under code “F” for payment of tax liability using securities.

Which Sarepta (SRPT) equity awards triggered the tax withholding for Cristin Rothfuss?

The tax withholding arose from restricted stock units that vested from two prior grants. One grant was dated March 7, 2022, and the other March 6, 2023, with shares withheld upon vesting to cover required tax obligations.

What does transaction code “F” mean in Cristin Rothfuss’s Sarepta (SRPT) Form 4?

Transaction code “F” indicates shares used to pay an exercise price or tax liability. In this case, Sarepta withheld common shares at $16.95 each to satisfy Rothfuss’s tax obligations when her restricted stock units from 2022 and 2023 vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/11/2026 - 08:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rothfuss Cristin

(Last) (First) (Middle)

215 FIRST STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		F(1)		484	D	$16.95	138,864	D
Common Stock	03/09/2026		F(2)		346	D	$16.95	138,518	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022.

2. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023.

	/s/ Cristin L. Rothfuss	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.